The Discovery and Development of the N‐Substituted trans‐3,4‐Dimethyl‐4‐(3′‐hydroxyphenyl)piperidine Class of Pure Opioid Receptor Antagonists |
| |
| Authors: | Dr. F. Ivy Carroll Dr. Roland E. Dolle |
| |
| Affiliation: | 1. Research Triangle Institute, Center for Organic and Medicinal Chemistry, 3040 Cornwallis Road, Research Triangle Park, NC 27709 (USA);2. Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421‐7994 (USA) |
| |
| Abstract: | N‐Substituted trans‐3,4‐dimethyl‐4‐(3‐hydroxyphenyl)piperidines are a class of pure opioid receptor antagonists with a novel pharmacophore. This opioid receptor antagonist pharmacophore was used as a lead structure to design and develop several interesting and useful opioid receptor antagonists. In this review we describe: 1) early SAR studies that led to the discovery of LY255582 and analogues that are nonselective opioid receptor antagonists developed for the treatment of obesity; 2) the discovery and commercialization of LY246736 (alvimopan; ENTEREG®), a peripherally selective opioid receptor antagonist that accelerates the time to upper and lower GI recovery following surgeries that include partial bowel resection with primary anastomosis; and 3) the discovery and development of the potent and selective κ opioid receptor antagonist JDTic and analogues as potential pharmacotherapies for treating depression, anxiety, and substance abuse (nicotine, alcohol, and cocaine). In addition, the use of JDTic for obtaining the X‐ray structure of the human κ opioid receptor is discussed. |
| |
| Keywords: | alvimopan drug design JDTic medicinal chemistry opioid antagonists |
|
|
